Search Results for “Roche” – Page 24 – media

FDA Approval for Eversense – Continuous Glucose Monitoring System

The FDA has finally approved to market the implantable continuous glucose monitoring system named Eversense, from Senseonics, in the United States.
- Source: MobiHealthNews
- 962
- June 27, 2018
diabetes digital health mHealth New Approvals
FDA Anounces Restricted use of Keytruda & Tecentriq Against Bladder Cancer

Keytruda is now allowed only for the patients whose tumor expression levels of the biomarker PD-L1 meet a combined positive score of 10 or higher. Tecentriq can only be used where PD-L1 immune cells can cover only 5% or more of their tumor area.
- Source: FiercePharma
- 777
- June 26, 2018
bladder cancer Company Insights Merck Roche
One More Approval for Merck’s Keytruda

On Wednesday, a day after Keytruda got the thumbs up for cervical cancer, the drug was approved for treatment of a rare form of non-Hodgkins lymphoma patients who cancer returned after at least two previous treatment lines. Last year, Keytruda also got an indication for classical Hodgkin lymphoma.
- Source: Fierce Pharma
- 716
- June 15, 2018
cancer Merck New Approvals non-Hodgkin lymphoma
FDA Considering Comments on SaMD Precertification Program

Healthcare industry stakeholders say the FDA should consider a type of measuring stick when evaluating a vendor’s cybersecurity culture to decide whether it meets the requirements for the agency’s proposed fast-past program for premarket approval of "software as a medical device" products (SaMD). Until the end of the last month, the FDA accepted proposals on its working model for a SaMD pre-approval program
- Source: Healthcare Info Security
- 731
- June 14, 2018
digital health FDA Market Views medical device
Healthcare Innovation Led By US and China

Global healthcare is being led by the US with China following close behind. Europe is simply being a spectator to the developments that are unfolding on a global level.
- Source: Ddu
- 737
- May 29, 2018
China healthcare Market Views USA
Mercks to Lead Squamous Lung Cancer Treatment With Keytruda

Pharma giant Merck & Co. revealed Keytruda had perfectly completed its final-stage research on the drug for previously untreated patients with skin cancer, who represent about 25% to 30% of the overall market.
- Source: Ddu
- 640
- May 24, 2018
cancer Company Insight Merck
Health-Check-Up Through Sweat Monitoring Wearable Device

Cincinnati-based startup Eccrine System has developed a health wearable devices called Sweatronics which tracks your health using sweat. Other bodily fluids like urine and blood contain plenty of the body information’s but are not as easy to collect. However, Sweatronics needs only sweat samples that is produces automatically while working or even sleeping.
- Source: Ddu
- 1,663
- May 24, 2018
digital health mHealth New Approvals
Rise in China’s Global Pharma Market up to $175 billion by 2022 – Market Prediction

Though the US stands first in the race in terms of sales and growth, it is highly believed that China would reach the peak in the pharma market by 2022. At present, since there has been a decrease in public health funding, there has been a slight fall in pharmerging countries like Brazil, Russia, India and China (BRIC). But it is believed that the condition of these pharmerging countries will improve in the next five years [1].
- Source: Ddu
- 822
- May 24, 2018
China Market Views pharmaceutical drugs
Ascletis files for Hong Kong IPO as floodgates open to prerevenue biotechs

Ascletis Pharma has become the first company to seek to list (PDF) in Hong Kong under the exchange’s new, more relaxed rules on biotech IPOs. The antiviral disease specialist will use the cash to win approvals for hepatitis C drugs licensed from Roche and Presidio Pharmaceuticals.
- Source: Fierce Pharma
- 858
- May 14, 2018
Market Views
Biotechnology Company Abpro postpones $69M IPO

According to reports, the biotechnology company Abpro has rescheduled its $96 million IPO, delaying a capital infusion it hoped would support the first clinical trials of its lead product candidates over the next year.
- Source: Ddu
- 606
- May 14, 2018
biotech Company Insights IPO

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.